Answers are grounded in this paper and cite their sources.
ackground: Suicide is still a biologically mystery process that can cause high rate of human mortality (1.3%) worldwide. The complex risk factors for behavioral or ideational change have great healthcare consequences and huge socioeconomic burden worldwide. Situation and knowledge: Influenced by complex risk factors, clinical suicide prevention and treatment progress needs ever-changing disease diagnosis and supportive biotechnology. Bridging the gap between molecular knowledge and suicide behaviors has great medical or pharmaceutical importance. Medical knowledge between east and west is compared and integrated. Recent results: Fortunately, an accelerate of neurobiology and psychopharmacology advances makes suicide treatment and intervention growing practical and manageable. Neural-psychiatric evidence and association profoundly impacts on the outcomes and efficacy of suicide prevention and therapeutics. The complex nature of human suicide (a hybrid and overlapping for genetics, epigenetics, transcriptome, proteomics, metabolomics data) is well discovered in different types of psychiatric diseases and outlook of neurobiology (brain anatomy, chemistry and functionality). Discussion: Immediate medical success (molecular targeting and curative therapies) in the clinic will be based on high-quality pharmaceutical study and biomedical progresses (achieving long-lasting and low toxic drugs or biotherapies). Certainly, a great deal of neurobiological and neuropsychiatry treatment study can create new hope for clinical strategies and paradigms for human suicide. Conclusion: Next generation of clinical suicide prediction, pharmacology and therapeutic landscapes will be developed in the near future.
No takes yet. Share an insight, caveat, or question.
Lu et al. (2025) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: